	Title	Authors	Number of URL Namespaces	Number of Regex Namespaces	Number of URL Annotations	Number of Regex Annotations	Number of Local Annotations	Number of Nodes	Number of Edges	Number of Citations	Number of Authors	Network Density	Number of Components	Number of Warnings
misc/damesquita2018.bel	Curation of Neurodegeneration in BEL (CONIB)	Trusha Adeshara, Rana Al Disi, Daniel Domingo-Fernández, Yojana Gadiya, Stephan Gebel, Sepehr Golriz, Charles Tapley Hoyt, Kristian Kolpeja, Sandra Spalek, Esther Wollert, Lingling Xu	21	17	12	9	35	51	120	1	23	4.71E-02	1	0
misc/gant2018.bel	FK506-Binding Protein 12.6/1b, a Negative Regulator of [Ca2], Rescues Memory and Restores Genomic Regulation in the Hippocampus of Aging Rats	Lingling Xu	5	0	4	0	0	30	51	1	7	5.86E-02	1	0
misc/maniati2019.bel	New insights into the role of microRNAs and long noncoding RNAs in most common neurodegenerative diseases	Sandra Spalek	8	0	4	1	0	94	181	1	5	2.07E-02	2	0
hpoxia/russo2019.bel	Hypoxia and Inflammation as a Consequence of β-Fibril Accumulation: A Perspective View for New Potential Therapeutic Targets.	Yojana Gadiya	8	3	2	1	0	103	160	1	7	1.52E-02	3	0
nfkb/bhardwaj2015.bel	RelB/p50 complexes regulate cytokine-induced YKL-40 expression	Sandra Spalek	5	1	4	1	0	37	92	1	10	6.91E-02	2	0
nfkb/chen2012.bel	Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.	Esther Wollert	6	1	3	1	0	20	35	1	9	9.21E-02	1	0
nfkb/marwarha2017.bel	Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) - a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease	Sandra Spalek	7	1	6	1	0	144	305	1	2	1.48E-02	1	0
nfkb/seo2017.bel	Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease	Esther Wollert	7	1	5	1	0	134	259	1	3	1.45E-02	1	0
nfkb/shi2016.bel	Upstream regulators and downstream effectors of NF-κBinAlzheimer's disease	Esther Wollert	8	1	5	1	0	99	218	1	10	2.25E-02	1	0
nfkb/srinivasan2015.bel	Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis	Sandra Spalek	6	0	4	1	0	75	154	1	2	2.77E-02	1	0
ms/boxberger209.bel	Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases.	Yojana Gadiya	11	5	8	1	0	195	451	1	3	1.19E-02	3	0
ms/brownlee2016.bel	Diagnosis of multiple sclerosis: progress and challenges	Trusha Adeshara	11	2	9	1	0	76	126	1	4	2.21E-02	3	0
ms/cappa2017.bel	Pediatric Multiple Sclerosis: Genes, Environment, and a Comprehensive Therapeutic Approach.	Yojana Gadiya	8	4	6	1	0	89	137	1	3	1.75E-02	5	0
ms/comi2016.bel	Evolving concepts in the treatment of relapsing multiple sclerosis	Trusha Adeshara	9	1	8	1	0	76	86	1	4	1.51E-02	2	0
ms/correale2017.bel	Progressive multiple sclerosis: from pathogenic mechanisms to treatment	Yojana Gadiya	7	1	7	1	0	177	317	1	4	1.02E-02	4	1
ms/doshi2016.bel	Multiple sclerosis, a treatable disease.	Yojana Gadiya	9	2	3	0	0	95	151	1	2	1.69E-02	2	0
ms/garg2015.bel	An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosi	Trusha Adeshara	10	0	6	1	0	142	219	1	2	1.09E-02	1	0
ms/ontaneda2016.bel	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function	Trusha Adeshara	11	2	9	1	0	54	72	1	4	2.52E-02	3	0
ms/wang2019.bel	Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis	Trusha Adeshara	12	2	8	1	0	147	362	1	4	1.69E-02	3	0
hdac6/carlomagno2017.bel	An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.	Yojana Gadiya	4	1	3	1	0	39	84	1	11	5.67E-02	1	0
hdac6/cohen2011.bel	The acetylation of tau inhibits its function and promotes pathological tau aggregation.	Yojana Gadiya	6	0	5	1	0	49	99	1	7	4.21E-02	1	0
hdac6/cook2014.bel	Acetylation: a new key to unlock tau's role in neurodegeneration..	Yojana Gadiya	9	1	6	1	0	72	182	1	5	3.56E-02	1	0
hdac6/deydewalle2012.bel	HDAC6 at the Intersection of Neuroprotection and Neurodegeneration.	Yojana Gadiya	8	1	5	1	0	95	178	1	3	1.99E-02	3	0
hdac6/fan2018.bel	he novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.	Yojana Gadiya	11	1	4	1	0	44	91	1	4	4.81E-02	1	0
hdac6/iaconelli2015.bel	HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.	Yojana Gadiya	6	1	2	1	0	34	99	1	8	8.82E-02	1	0
hdac6/iaconelli2019.bel	HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.	Yojana Gadiya	9	1	5	1	0	111	231	1	3	1.89E-02	2	0
hdac6/ma2018.bel	Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.	Yojana Gadiya	6	1	3	1	0	23	44	1	5	8.70E-02	1	0
hdac6/min2018.bel	SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy	Yojana Gadiya	6	0	4	1	0	26	45	1	10	6.92E-02	2	0
hdac6/park2018.bel	Degradation or aggregation: the ramifications of post-translational modifications on tau.	Yojana Gadiya	7	0	3	1	0	99	231	1	4	2.38E-02	3	0
app/elliott2018.bel	A role for APP in Wnt signalling links synapse loss with β-amyloid production.	Esther Wollert	5	1	10	1	0	22	60	1	13	1.30E-01	1	0
app/hussain1999.bel	Identification of a novel aspartic protease (Asp 2) as beta-secretase	Rana Aldisi	15	2	10	1	0	11	19	1	15	1.73E-01	1	0
app/maccecchini2012.bel	Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-b peptide and s levels: target engagement, tolerability and pharmacokinetics in humans	Lingling Xu	15	4	10	7	3	11	13	1	6	1.18E-01	1	0
app/morsy2018.bel	Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer’s Disease	Esther Wollert	15	4	11	1	0	85	119	1	2	1.67E-02	2	0
app/mroczko2018.bel	Amyloid β oligomers (AβOs) in Alzheimer’s disease	Esther Wollert	6	0	5	1	0	57	97	1	5	3.04E-02	1	0
app/thinakaran2008.bel	Amyloid Precursor Protein Trafficking, Processing, and Function	Esther Wollert	6	0	10	1	0	40	48	1	2	3.08E-02	1	0
app/yeon2007.bel	Effects of peptides derived from BACE1 catalytic domain on APP processing	Rana Aldisi	15	2	10	1	0	10	30	1	4	3.33E-01	1	0
app/zhang2011.bel	APP processing in Alzheimer's disease	Sandra Spalek	6	1	5	0	1	144	265	1	4	1.29E-02	4	0
app/zhang2012.bel	Proteolytic processing of Alzeimer's beta-amyloid precursor protein	Sandra Spalek	9	0	10	0	1	132	226	1	4	1.31E-02	3	0
biomarkers/cdr_sb_associations.bel	CDR-SB Associations	Lukas Beniusis, Charles Tapley Hoyt, and Daniel Domingo-Fernández	7	2	6	1	2	93	166	30	350	1.94E-02	7	0
biomarkers/cdr_story.bel	KANSL1 Subgraph and CDR Story	Sepehr Golriz, Daniel Domingo-Fernández, Charles Tapley Hoyt	9	0	11	0	1	128	209	15	139	1.29E-02	1	0
biomarkers/genetics.bel	Genetic Biomarkers for Alzheimer's Disease	Sepehr Golriz, Daniel Domingo-Fernández, Charles Tapley Hoyt	10	1	8	1	0	399	1085	72	1103	6.83E-03	6	0
biomarkers/neuroimaging.bel	Neuroimaging Biomarkers	Sepehr Golriz, Daniel Domingo-Fernández, Charles Tapley Hoyt	8	1	7	0	0	130	310	40	340	1.85E-02	2	0
mtor/ryskalin2018.bel	mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders	Sandra Spalek	8	1	7	1	0	129	344	1	5	2.08E-02	2	0
mitochondrial-dysfunction/qi2019.bel	Dynamin-related protein 1: A critical protein in the pathogenesis of neural system dysfunctions and neurodegenerative diseases.	Yojana Gadiya	11	4	7	1	0	206	527	1	4	1.25E-02	1	0
receptors/albuquerque2009.bel	albuquerque2009	Rana Aldisi	15	4	10	1	0	269	498	1	4	6.91E-03	9	0
receptors/buckingham2009.bel	Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.	Rana Aldisi	15	2	10	1	0	234	564	1	4	1.03E-02	2	0
receptors/changeux2012.bel	The Nicotinic Acetylcholine Receptor: The Founding Father of the Pentameric Ligand-gated Ion Channel Superfamily	Lingling Xu	13	1	10	0	0	54	61	1	1	2.13E-02	2	0
receptors/choi2014.bel	Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.	Rana Aldisi	15	2	10	1	0	97	208	1	4	2.23E-02	1	0
receptors/corradi2016.bel	Understanding the Bases of Function and Modulation of alpha7 Nicotinic Receptors: Implications for Drug Discovery.	Trusha Adeshara	12	2	7	1	0	59	109	1	2	3.19E-02	1	0
receptors/dani2007.bel	Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System	Esther Wollert and Charles Tapley Hoyt	6	1	10	1	0	86	196	1	2	2.68E-02	2	0
receptors/dani2015.bel	Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine	Esther Wollert	15	3	10	1	0	23	33	1	1	6.52E-02	2	0
receptors/djouma2006.bel	The CRF1 receptor antagonist, antalarmin, reverses isolation-induced up-regulation of dopamine D2 receptors in the amygdala and nucleus accumbens of fawn-hooded rats	Lingling Xu	15	4	10	1	0	18	34	1	4	1.11E-01	1	0
receptors/echeverria2012.bel	Cotinine: a potential new therapeutic agent against Alzheimer's disease	Trusha Adeshara	11	2	9	1	0	78	174	1	2	2.90E-02	1	0
receptors/ferreira-vieira2016.bel	Alzheimer's Disease: Targeting the Cholinergic System	Sandra Spalek	15	4	10	1	0	161	300	1	4	1.16E-02	3	0
receptors/forest2019.bel	Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity	Trusha Adeshara	10	1	6	1	0	74	120	1	2	2.22E-02	2	0
receptors/francis2016.bel	Interplay of neurotransmitters in Alzheimer's disease	Rana Aldisi	5	0	5	1	0	43	83	1	1	4.60E-02	1	0
receptors/jiang2014.bel	M1 muscarinic acetylcholine receptor in Alzheimer’s disease	Rana Aldisi	15	2	10	1	0	134	234	1	7	1.31E-02	4	0
receptors/kabbani2018.bel	Beyond the Channel: Metabotropic Signaling by Nicotinic Receptors.	Trusha Adeshara	12	2	7	1	0	115	224	1	2	1.71E-02	2	0
receptors/kalkman2016.bel	Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders	Trusha Adeshara	12	2	7	1	0	171	330	1	2	1.14E-02	2	0
receptors/king2015.bel	Identification and Characterization of a G Protein-binding Cluster in alpha7 Nicotinic Acetylcholine Receptors	Rana Aldisi	15	4	10	1	0	39	90	1	5	6.07E-02	2	0
receptors/lombardo2015.bel	Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment	Sandra Spalek	15	4	10	1	0	124	246	1	2	1.61E-02	2	0
receptors/lombardo2015b.bel	A role for b2* nicotinic receptors in a model of local amyloid pathology induced in dentate gyrus	Sandra Spalek	15	1	10	1	0	21	40	1	4	9.52E-02	1	0
receptors/lorenz2014.bel	Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease	Lingling Xu	13	1	10	0	0	9	21	1	8	2.92E-01	1	0
receptors/majdi2019.bel	Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review.	Trusha Adeshara	12	2	9	1	0	80	139	1	4	2.20E-02	1	0
receptors/mandrekar2011.bel	Nuclear receptors as therapeutic targets for Alzheimer's disease.	Esther Wollert	10	2	10	1	0	82	169	1	2	2.54E-02	4	0
receptors/matta2017.bel	NACHO Mediates Nicotinic Acetylcholine Receptor Function throughout the Brain	Sandra Spalek	15	1	10	1	0	63	120	1	7	3.07E-02	1	0
receptors/miwa2011.bel	Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses	Sandra Spalek	15	1	10	1	0	106	237	1	3	2.13E-02	3	0
receptors/mufson2008.bel	Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications	Rana Aldisi	9	0	5	1	0	175	308	1	4	1.01E-02	2	0
receptors/nordberg2001.bel	Nicotinic Receptor Abnormalities of Alzheimer’s Disease: Therapeutic Implications	Sandra Spalek	15	4	10	1	0	59	124	1	1	3.62E-02	2	2
receptors/post-munson2017.bel	B-973, a novel piperazine positive allosteric modulator of the α7 nicotinic acetylcholine receptor	Sandra Spalek	15	4	10	1	0	13	20	1	14	1.28E-01	1	0
receptors/ren2007.bel	The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice	Sandra Spalek	15	4	10	1	0	13	13	1	8	8.33E-02	1	0
receptors/sadigh-eteghad2015.bel	Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice	Rana Aldisi	15	4	10	1	0	11	35	1	5	3.18E-01	1	0
receptors/taly2009.bel	Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system	Rana Aldisi	15	4	10	1	0	117	210	1	5	1.55E-02	11	0
receptors/valles2011.bel	Chaperoning α7 neuronal nicotinic acetylcholine receptors	Esther Wollert	13	3	10	1	0	76	113	1	2	1.98E-02	2	0
receptors/walsh2008.bel	Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype	Esther Wollert	15	4	10	1	0	8	12	1	7	2.14E-01	1	0
receptors/wang2016.bel	Estrogen receptor-α is localized to neurofibrillary tangles in Alzheimer's disease	Esther Wollert	13	1	10	0	0	10	17	1	9	1.89E-01	1	0
receptors/wu2011.bel	Naturally-expressed nicotinic acetylcholine receptor subtypes	Esther Wollert	15	4	10	1	0	49	82	1	2	3.49E-02	2	0
receptors/zoli2018.bel	Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors.	Lingling Xu	13	3	10	0	0	110	208	1	4	1.73E-02	2	2
immunotherapy/jadhav2013.bel	Protein truncation as a common denominator of human neurodegenerative foldopathies	Yojana Gadiya	7	1	4	1	0	151	306	1	3	1.35E-02	1	0
immunotherapy/kontsekova2014.bel	Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease	Yojana Gadiya	5	0	2	1	0	31	51	1	1	5.48E-02	1	1
immunotherapy/kontsekova2014_2.bel	First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model	Yojana Gadiya	6	0	4	1	0	44	71	1	5	3.75E-02	1	0
adnp/hacohen-kleiman2018.bel	Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome	Sandra Spalek	4	1	4	1	0	70	169	1	10	3.50E-02	1	0
adnp/sragovich2019.bel	The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse	Sandra Spalek	6	1	3	1	0	27	66	1	8	9.40E-02	1	0
adnp/van-dijck2019.bel	Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP	Esther Wollert	3	0	1	0	0	29	32	1	21	3.94E-02	1	0
adnp/ziv2018.bel	Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice	Sandra Spalek	4	1	3	1	0	12	29	1	10	2.20E-01	1	0
anatabine/caturegli2012.bel	Anatabine ameliorates experimental autoimmune thyroiditis.	Esther Wollert	5	0	3	1	0	16	20	1	7	8.33E-02	2	0
anatabine/paris2011.bel	Anatabine lowers Alzheimer's Aβ production in vitro and in vivo	Sandra Spalek	5	1	5	1	0	22	40	1	10	8.66E-02	1	0
anatabine/paris2013.bel	Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation	Sandra Spalek	14	4	10	1	0	25	78	1	9	1.30E-01	2	0
anatabine/paris2013b.bel	Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine	Sandra Spalek	15	4	10	1	0	25	82	1	8	1.37E-01	1	0
anatabine/paris2014.bel	Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice	Sandra Spalek	6	0	2	1	0	18	30	1	0	9.80E-02	1	0
anatabine/rosecrans2017.bel	Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons	Sandra Spalek	5	1	4	1	0	69	100	1	2	2.13E-02	3	0
anatabine/verma2015.bel	Chronic Anatabine Treatment Reduces Alzheimer ’ s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD	Esther Wollert	17	4	11	1	0	22	41	1	7	8.87E-02	1	0
anatabine/wang2009.bel	Silencing of PMT expression caused a surge of anatabine accumulation in tobacco	Sandra Spalek	17	4	11	1	0	13	21	1	6	1.35E-01	1	0
oxidative-stress/hybertson2011.bel	Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation	Sandra Spalek	15	4	11	1	0	156	318	1	4	1.32E-02	6	0
oxidative-stress/shefa2019.bel	Mitophagy links oxidative stress conditions and neurodegenerative diseases	Esther Wollert	8	1	4	1	0	84	165	1	7	2.37E-02	1	0
phagocytosis/deming2019.bel	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk	Yojana Gadiya	4	1	2	1	0	27	51	1	36	7.26E-02	2	0
pp2a/seshacharyulu2013.bel	Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer	Esther Wollert	15	4	11	1	0	88	151	1	4	1.97E-02	1	0
pp2a/shi2009.bel	Assembly and structure of protein phosphatase 2A	Sandra Spalek	15	4	11	1	0	67	179	1	1	4.05E-02	1	0
pp2a/sontag2014.bel	Protein phosphatase 2A dysfunction in Alzheimer’s disease	Sandra Spalek	15	4	11	1	0	126	426	1	2	2.70E-02	1	0
pp2a/terwel2002.bel	Axonal Transport, Tau Protein, and Neurodegeneration in Alzheimer’s Disease	Esther Wollert	16	4	11	1	0	43	61	1	3	3.38E-02	1	0
pp2a/torrent2012.bel	PP2A and Alzheimer Disease	Esther Wollert	15	4	11	1	0	48	110	1	2	4.88E-02	1	0
pp2a/wang2017.bel	Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo	Sandra Spalek	15	4	11	1	0	22	60	1	14	1.30E-01	1	0
huntington/decristo2019.bel	Meldonium improves Huntington's disease mitochondrial dysfunction by restoring peroxisome proliferator-activated receptor γ coactivator 1α expression.	Yojana Gadiya	18	4	11	1	0	46	64	1	12	3.09E-02	2	0
huntington/goh2018.bel	Huntington's disease: Neuropsychiatric manifestations of Huntington's disease	Esther Wollert	4	0	3	1	0	22	45	1	6	9.74E-02	1	0
huntington/jiang2012.bel	Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets	Yojana Gadiya	9	4	11	1	0	38	60	1	30	4.27E-02	1	0
huntington/jin2010.bel	The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease.	Yojana Gadiya	10	2	3	1	0	73	96	1	2	1.83E-02	4	0
huntington/loi2018.bel	Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease	Yojana Gadiya	9	4	11	1	0	37	68	1	4	5.11E-02	2	0
huntington/nguyen2016.bel	Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease	Trusha Adeshara	8	1	5	1	0	38	84	1	3	5.97E-02	2	0
huntington/pandey2018.bel	Huntington’s disease: the coming of age	Trusha Adeshara	12	3	6	1	0	223	348	1	2	7.03E-03	4	0
huntington/sarantos2012.bel	Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington’s Disease	Trusha Adeshara	9	0	5	1	0	76	167	1	4	2.93E-02	1	0
huntington/seong2010.bel	Huntingtin facilitates polycomb repressive complex 2	Yojana Gadiya	10	4	11	1	0	24	31	1	14	5.62E-02	3	0
hypoxia/zhang2011.bel	Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases.	Yojana Gadiya	10	2	5	1	0	139	255	1	5	1.33E-02	1	0
er-stress/bruch2017.bel	PERK activation mitigates tau pathology in vitro and in vivo.	Yojana Gadiya	8	4	5	1	0	76	194	1	10	3.40E-02	1	0
er-stress/doyle2011.bel	Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders	Trusha Adeshara	11	0	6	1	0	251	549	1	6	8.75E-03	3	2
er-stress/guo2019.bel	A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response	Yojana Gadiya	9	1	2	1	0	59	133	1	5	3.89E-02	1	0
er-stress/muneer2019.bel	Endoplasmic Reticulum Stress: Implications for Neuropsychiatric Disorders	Yojana Gadiya	15	4	11	1	0	97	143	1	2	1.54E-02	3	0
tfeb/bao2016.bel	Deacetylation of TFEB promotes fibrillar Aβ degradation by upregulating lysosomal biogenesis in microglia.	Yojana Gadiya	6	0	4	1	0	40	105	1	14	6.73E-02	1	0
tfeb/martini-stocia2016.bel	The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective.	Yojana Gadiya	8	1	4	1	0	116	234	1	4	1.75E-02	1	0
tfeb/martini-stoica2018.bel	TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading.	Yojana Gadiya	8	1	5	1	0	49	105	1	12	4.46E-02	2	0
tfeb/sardiello2016.bel	Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases	Yojana Gadiya	9	1	5	1	0	178	444	1	1	1.41E-02	2	0
proteostasis/brehme2014.bel	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Esther Wollert	15	4	10	1	0	31	54	1	12	5.81E-02	1	0
proteostasis/brehme2016.bel	Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity	Esther Wollert	15	4	11	1	0	48	83	1	2	3.68E-02	3	0
proteostasis/brekk2018.bel	Impairment of chaperone-mediated autophagy affects neuronal homeostasis through altered expression of DJ-1 and CRMP-2 proteins 	Trusha Adeshara	18	4	11	1	0	42	80	1	6	4.65E-02	1	0
proteostasis/chung2018.bel	Alzheimer’s disease and the autophagic-lysosomal system	Sandra Spalek	15	4	11	1	0	164	372	1	4	1.39E-02	1	0
proteostasis/ciechanover2013.bel	The Ubiquitin Proteasome System in Neurodegenerative Diseases: Sometimes the Chicken, Sometimes the Egg	Sandra Spalek	15	4	10	1	0	272	492	1	2	6.67E-03	4	0
proteostasis/ihara2012.bel	The Ubiquitin–Proteasome System and the Autophagic–Lysosomal System in Alzheimer Disease	Sandra Spalek	15	4	11	1	0	188	471	1	3	1.34E-02	7	0
proteostasis/kim2013.bel	Molecular Chaperone Functions in Protein Folding and Proteostasis	Esther Wollert	15	4	11	1	0	65	112	1	5	2.69E-02	2	0
proteostasis/kleiger2014.bel	Perilous journey: a tour of the ubiquitin–proteasome system	Sandra Spalek	15	4	10	1	0	58	94	1	2	2.84E-02	2	0
proteostasis/morimoto2015.bel	The Biology of Proteostasis in Aging and Disease	Esther Wollert	15	4	10	1	0	94	162	1	2	1.85E-02	2	0
proteostasis/nedelsky2008.bel	Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection	Sandra Spalek	15	4	11	1	0	127	243	1	3	1.52E-02	2	0
proteostasis/niforou2014.bel	Molecular chaperones and proteostasis regulation during redox imbalance	Esther Wollert	15	4	11	1	0	74	96	1	3	1.78E-02	3	0
proteostasis/taipale2014.bel	A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways	Sandra Spalek	15	4	10	1	0	288	566	1	10	6.85E-03	8	0
proteostasis/yu2014.bel	Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition	Esther Wollert	15	4	11	1	0	13	15	1	6	9.62E-02	2	0
snca/bengoa2017.bel	Alpha-synuclein oligomers: a new hope 	Esther Wollert	5	0	3	0	0	48	64	1	4	2.84E-02	2	0
snca/pieri2016.bel	Structural and functional properties of prefibrillar α-synuclein oligomers	Esther Wollert and Charles Tapley Hoyt	4	0	4	0	0	13	19	1	3	1.22E-01	1	0
antalarmin/alderman2018.bel	Corticotropin-releasing factor regulates caspase-3 and may protect developing zebrafish from stress-induced apoptosis	Lingling Xu	13	5	10	1	0	7	14	1	4	3.33E-01	1	0
antalarmin/dinopoulou2013.bel	The effect of CRH and its inhibitor, antalarmin, on in vitro growth of preantral mouse follicles, early embryo development, and steroidogenesis.	Lingling Xu	14	4	10	1	0	10	15	1	8	1.67E-01	1	0
antalarmin/lewis1996.bel	In Vivo and In Vitro Characterization of Antalarmin, a Nonpeptide Corticotropin-Releasing Hormone (CRH) Receptor Antagonist: Suppression of Pituitary ACTH Release and Peripheral Inflammation	Kristian Kolpeja	9	2	10	1	5	7	11	1	6	2.62E-01	1	0
tau/balaji2018.bel	Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems	Esther Wollert	15	4	11	1	0	27	52	1	5	7.41E-02	1	0
tau/baumann1993.bel	Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5	Sandra Spalek	13	2	10	0	0	20	70	1	5	1.84E-01	1	0
tau/biswas2016.bel	MMP-9 and MMP-2 Contribute to Neuronal Cell Death in iPSC Models of Frontotemporal Dementia with MAPT Mutations	Sandra Spalek	13	2	10	0	0	34	88	1	12	7.84E-02	1	0
tau/boland2018.bel	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing	Esther Wollert, Sandra Spalek, and Charles Tapley Hoyt	13	3	10	0	0	200	400	1	19	1.01E-02	3	0
tau/bulic2012.bel	Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease	Charles Tapley Hoyt	3	0	1	6	3	23	25	1	3	4.94E-02	1	0
tau/caballero2018.bel	Interplay of pathogenic forms of human tau with different autophagic pathways	Sandra Spalek	13	1	10	0	0	59	141	1	9	4.12E-02	1	0
tau/cabrales2017.bel	Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau	Sandra Spalek	13	2	10	0	0	57	116	1	6	3.63E-02	1	0
tau/chesser2013.bel	Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease	Rana Aldisi	8	0	5	1	0	117	296	1	3	2.18E-02	2	0
tau/cox2016.bel	Analysis of Isoform-specific Tau Aggregates Suggests a Common Toxic Mechanism Involving Similar Pathological Conformations and Axonal Transport Inhibition	Sandra Spalek	15	4	10	1	0	32	191	1	6	1.93E-01	1	0
tau/defelice2008.bel	Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers	Rana Aldisi	6	0	4	1	0	23	54	1	13	1.07E-01	1	0
tau/dennissen2016.bel	Adenosine A1 receptor antagonist 64627 alleviates axonopathy caused by human Tau ΔK280	Sandra Spalek	15	4	10	1	0	39	85	1	5	5.74E-02	1	8
tau/despres2017.bel	Identification of the Tau phosphorylation pattern that drives its aggregation	Kristian Kolpeja	13	1	10	0	2	12	21	1	11	1.59E-01	1	0
tau/evans2018.bel	Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways	Sandra Spalek	15	4	10	1	0	19	63	1	7	1.84E-01	2	0
tau/fatouros2012.bel	Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity	Esther Wollert	5	2	5	1	0	28	46	1	8	6.08E-02	1	0
tau/frandemiche2014.bel	Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers	Rana Aldisi, Sandra Spalek	5	0	3	0	0	26	74	1	8	1.14E-01	1	0
tau/joseph2017.bel	Anti-aggregant tau mutant promotes neurogenesis	Sandra Spalek, Esther Wollert	15	4	10	1	0	20	53	1	5	1.39E-01	1	0
tau/kanaan2011.bel	Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.	Lingling Xu	4	0	3	0	0	22	48	1	10	1.04E-01	1	0
tau/kaniyappan2017.bel	Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability	Sandra Spalek, Esther Wollert	15	4	11	1	0	37	54	1	4	4.05E-02	1	0
tau/lee2013.bel	Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system.	Esther Wollert, Sandra Spalek	8	1	3	0	0	64	116	1	3	2.88E-02	1	0
tau/martini‐stoica2018.bel	TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading	Lingling Xu, Sandra Spalek	7	0	3	1	0	37	60	1	12	4.50E-02	1	0
tau/mirbaha2015.bel	Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation	Esther Wollert, Sandra Spalek	5	0	3	0	0	14	25	1	5	1.37E-01	2	0
tau/mirbaha2018.bel	Inert and seed-competent tau monomers suggest structural origins of aggregation	Esther Wollert, Sandra Spalek	4	1	3	0	0	10	15	1	12	1.67E-01	1	0
tau/miyata2011.bel	Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies	Sandra Spalek	7	1	6	1	0	119	236	1	5	1.68E-02	2	0
tau/musi2018.bel	Tau protein aggregation is associated with cellular senescence in the brain	Sandra Spalek	13	1	10	0	0	77	152	1	7	2.60E-02	2	0
tau/nobuhara2017.bel	Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro	Rana Aldisi, Sandra Spalek	5	0	4	1	1	19	48	1	21	1.40E-01	1	0
tau/paris2014.bel	The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation*	Sandra Spalek, Esther Wollert	15	4	11	1	0	50	119	1	9	4.86E-02	1	0
tau/park2012.bel	Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.	Lingling Xu, Sandra Spalek	7	0	3	1	0	39	104	1	8	7.02E-02	2	0
tau/pickhardt2018.bel	Screening of a neuronal cell model of Tau pathology for therapeutic compounds	Esther Wollert, Sandra Spalek	5	1	1	0	0	62	105	1	8	2.78E-02	1	0
tau/pir2017.bel	Caenorhabditis elegans models of tauopathy	Sandra Spalek, Esther Wollert	15	4	11	1	0	112	187	1	3	1.50E-02	1	0
tau/rauch2018.bel	Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs)	Sandra Spalek	15	4	10	1	0	28	61	1	9	8.07E-02	3	0
tau/ryan2019.bel	The O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease	Sandra Spalek	10	1	5	1	0	117	217	1	7	1.60E-02	3	0
tau/saidi2015.bel	Carboxy terminus heat shock protein 70 interacting protein reduces tau-associated degenerative changes	Sandra Spalek, Esther Wollert	15	4	11	1	0	52	115	1	7	4.34E-02	1	0
tau/schweig2017.bel	Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.	Esther Wollert, Sandra Spalek	5	0	6	1	0	25	63	1	8	1.05E-01	1	0
tau/shafiei2017.bel	Tau oligomers-Cytotoxicity, propagation, and mitochondrial damage	Sandra Spalek and Charles Tapley Hoyt	6	0	4	0	1	69	134	1	3	2.86E-02	1	0
tau/shelton2017.bel	Imbalances in the Hsp90 Chaperone Machinery: Implications for Tauopathies	Esther Wollert, Sandra Spalek	7	1	5	1	0	106	208	1	3	1.87E-02	3	0
tau/simic2016.bel	Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies	Kristian Kolpeja, Esther Wollert	14	3	10	1	1	113	217	1	12	1.71E-02	4	0
tau/takeda2015.bel	Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain	Esther Wollert, Sandra Spalek	5	0	2	1	0	19	38	1	15	1.11E-01	1	0
tau/tarasoffconway2015.bel	Clearance systems in the brain-implications for Alzheimer disease.	Lingling Xu, Esther Wollert	13	1	10	1	0	95	173	1	16	1.94E-02	3	12
tau/tiernan2016.bel	Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.	Rana Aldisi, Esther Wollert	4	0	3	0	0	12	30	1	7	2.27E-01	1	0
tau/wang2015.bel	Tau in physiology and pathology	Sandra Spalek, Esther Wollert	6	1	3	1	0	174	429	1	2	1.43E-02	2	0
tau/ward2012.bel	Tau oligomers and tau toxicity in neurodegenerative disease	Sandra Spalek	6	0	2	0	1	30	63	1	4	7.24E-02	1	0
tau/xin2018.bel	Clearance of Amyloid Beta and Tau in Alzheimer’s Disease:from Mechanisms to Therapy	Sandra Spalek	15	4	10	1	0	146	281	1	4	1.33E-02	1	5
tau/yamada2017.bel	Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology	Lingling Xu, Esther Wollert	5	1	3	1	0	38	48	1	1	3.41E-02	2	0
tau/yamada2018.bel	The sulfation code for propagation of neurodegeneration	Sandra Spalek	6	0	3	0	0	30	50	1	2	5.75E-02	1	0
tau/taubase/tau_biochemistry.bel	Tau Biochemistry	Kristian Kolpeja	8	0	5	1	5	104	196	6	48	1.83E-02	2	0
tau/taubase/tau_interaction_partners.bel	Tau and Interaction Partners	Kristian Kolpeja	11	1	6	1	4	185	514	29	153	1.51E-02	2	0
tau/taubase/tau_mitochondria.bel	Tau Effect on Mitochondria	Kristian Kolpeja, Sandra Spalek	15	4	11	1	2	45	117	1	6	5.91E-02	1	0
tau/taubase/tau_modifications.bel	Tau Modifications	Kristian Kolpeja, Esther Wollert, Sandra Spalek	13	5	8	1	22	1054	2694	188	1202	2.43E-03	4	0
tardbp/ayala2008.bel	TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression.	Yojana Gadiya	8	3	4	2	0	87	164	1	3	2.19E-02	3	0
tardbp/chang2013.bel	Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function.	Yojana Gadiya	6	2	2	2	0	32	59	1	5	5.95E-02	1	0
tardbp/monahan2016.bel	Stress granules at the intersection of autophagy and ALS	Sandra Spalek	7	0	5	1	0	129	270	1	3	1.64E-02	3	0
tardbp/paolicelli2017.bel	TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss.	Yojana Gadiya	9	3	5	1	0	62	93	1	14	2.46E-02	1	0
tardbp/prasad2019.bel	Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis.	Yojana Gadiya	10	4	11	1	0	320	719	1	5	7.04E-03	1	22
tardbp/uchino2015.bel	Incidence and extent of TDP-43 accumulation in aging human brain	Yojana Gadiya	8	4	11	1	0	9	15	1	10	2.08E-01	1	0
tardbp/xia2016.bel	TDP-43 loss of function increases TFEB activity and blocks autophagosome–lysosome fusion	Sandra Spalek	5	0	3	1	0	92	197	1	11	2.35E-02	1	0
inflammasome/heneka2017.bel	Inflammasome activation and innate immunity in Alzheimer’s disease	Sandra Spalek	13	2	10	0	0	24	41	1	1	7.43E-02	1	0
inflammasome/latz2013.bel	Activation and regulation of the inflammasomes	Esther Wollert	13	0	10	0	0	124	187	1	3	1.23E-02	6	0
inflammasome/liu2014.bel	The role of inflammasome in Alzheimer’s disease	Sandra Spalek	13	3	10	0	0	70	168	1	2	3.48E-02	2	0
inflammasome/olsen2016.bel	Inﬂammasome Involvement in Alzheimer’s Disease	Esther Wollert	13	2	10	0	0	46	88	1	2	4.25E-02	2	0
inflammasome/pape2019.bel	Immunoneuropsychiatry — novel perspectives on brain disorders	Trusha Adeshara	11	1	7	1	0	204	338	1	4	8.16E-03	7	0
inflammasome/paul2000.bel	Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.	Yojana Gadiya	5	1	2	1	0	75	156	1	4	2.81E-02	1	0
